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ABSTRACT Patients with lupus erythematosus (lE) that have discoid le-
sions who fulfill the four diagnostic criteria of systemic lupus erythema-
tosus (SlE) with only mucocutaneous findings and antinuclear antibody 
(AnA) positivity were classified as borderline SlE in the literature. Objec-
tive of this study was to determine the place of borderline SlE with discoid 
lesions on the lE spectrum according to the lupus band test (lBT). lesional 
and sun-protected non-lesional (SPnl) skin lBTs of 94 patients with lE that 
had discoid lesions were retrospectively evaluated. Firstly, patients were 
divided into two main groups: discoid lE (DlE; group A) and SlE (Group 
B); three subgroups were then classified as DlE (Group A), borderline SlE 
(Group B1) and SlE (Group B2) using another method. Each group had its 
own comparisons. Immunoreactant (IR) deposition was observed on the 
lesional skin in all patients and on the SPnl skin in 42 (44.7%). In patients 
with borderline SlE, the deposition of IgM was lower on the lesional lBTs, 
whereas isolated IgG was higher than SlE; thus, it shows similarity with 
DlE. Additionally, it was also closer to DlE because of the low deposition 
of C3, multiple IRs, and a double conjugate of IRs on the SPnl skin. How-
ever, it showed similarity with SlE in the high percentage of lBT positivity 
and more immunoglobulin M (IgM) and immunoglobulin G (IgG) deposi-
tion on the SPnl skin. The deposition of multiple conjugates on SPnl skin 
in patients with lE with discoid lesions may reflect systemic involvement. 
Despite the fact that lBT positivity on SPnl skin in borderline SlE was 
higher than DlE, less deposition of multiple conjugates compared to SlE 
indicates that the classification of borderline SlE with discoid lesions in 
the lE spectrum is questionable. 
KEY WORDS: lupus band test, discoid lupus erythematosus, borderline 
systemic lupus erythematosus 
INTRODUCTION
lupus erythematosus (lE) is a chronic autoim-
mune disease. Its clinical findings are characterized by 
a wide spectrum that varies from mild cutaneous in-
volvement to life-threatening visceral manifestations. 
The most frequent clinical subtype of cutaneous lE 
(ClE) is discoid lE (DlE), presenting with discoid le-
sions (1-4). Such discoid lesions are characterized by 
coin-shaped, well defined, erythematous plaques 
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located mainly on sun-exposed areas, and they can 
either be limited to only the skin or a part of the sys-
temic disease (1-3). The presence of classical discoid 
rash is one of the most frequently observed American 
College of Rheumatology (ACR) diagnostic criteria of 
SlE (4). Such discoid lesions can be the initial symp-
tom of SlE in approximately 10% of patients, or they 
may occur in the course of the disease in 20-25% of 
patients (1-3). Although some researchers reveal that 
discoid lesions are the benignity indicators of SlE, 
some recent studies have shown that disease activity 
and severity are the same in patients with SlE with or 
without discoid lesions (5-7). Thus, the importance of 
correct diagnosis and close follow-up in high-risk pa-
tients with discoid lesions has been emphasized (7,8).
As is known, the diagnosis of SlE is based on the 
presence of 4 of the 11 ACR criteria. However, patients 
who fulfill these four criteria only with skin-related 
findings (discoid rash, malar rash, photosensitivity, 
oral ulcers) have been a matter of discussion in the lit-
erature. Because of the absence of systemic involve-
ment in most of these patients with discoid lesions, 
they can be easily misdiagnosed or overdiagnosed as 
having SlE (1,2). Thus, Vasquez et al. have suggested 
classifying patients with discoid lesions (n=32) who 
only have mucocutaneous findings (≥3 criteria) and 
antinuclear antibody (AnA) positivity into a separate 
subgroup termed borderline DlE/SlE that is placed 
between DlE and SlE. It has been observed that the 
lesion distribution and autoantibody profiles of the 
patients in this subgroup show great similarity to DlE; 
thus the need for non-mucocutaneous and non-AnA 
diagnosis criteria have been emphasized in order to 
reduce the possibility of excess SlE diagnosis accord-
ing to the ACR criteria in such patients (9).
The lupus band test (lBT), a direct immunofluo-
rescence (DIF) examination of skin biopsy, is com-
monly used in the diagnosis of ClE and SlE. It has 
been noted that the lBT positivity on sun-protected 
non-lesional (SPnl) skin can be useful in the diag-
nosis of SlE in patients with insufficient clinical and 
serological profiles (10-15). Positive lBT results on 
SPnl skin can be found in patients with SlE earlier 
than the other laboratory tests, and the sensitivity of 
lBT is higher in the diagnosis of active disease (10-
14). However, the data in the literature showing the 
immune deposition on SPnl skin in patients with DlE 
is limited (16-20). 
In this study we aimed to determine the place of 
borderline SlE in the lE spectrum by comparing the 
lBT results (on lesional and SPnl skin) of our patients 
with lE with discoid lesions whom we have classified 
into three subgroups: DlE, borderline SlE, and SlE. 
PATIENTS AND METHODS
The files of 94 patients with lE that had classical 
discoid lesions, who had been diagnosed based on 
clinical and histopathological findings, were retro-
spectively evaluated in this study. Only patients with 
both lBTs on lesional and SPnl skin (biopsies were 
taken simultaneously) were included. According to 
the lE classification criteria defined by Gilliam and 
Sontheimer (21), patients who had any other distinct 
lE-specific skin lesion such as classical discoid lesions, 
drug-induced DlE history, or patients with a history 
of any topical or systemic corticosteroid and immu-
nosuppressive drug use within one month before the 
skin biopsy and patients with insufficient file records 
were excluded from the study. The study was ap-
proved by the hospital ethics committee before data 
collection. 
Our patients with lE that had discoid lesions were 
classified according to the ACR criteria. Patients sat-
isfying <4 criteria were classified in the DlE group 
(Group A), and patients having ≥4 criteria were classi-
fied in the SlE group (Group B) (1-4). Additionally, all 
patients with discoid lesions were divided into three 
subgroups according to the classification defined by 
Vasquez et al.: DlE (Group A; with <4 ACR criteria), bor-
derline SlE (Group B1; with either 2 or 3 skin-related 
ACR criteria including self-reported malar eruption, 
oral ulcers and photosensitivity in addition to discoid 
lesions, and positive findings of AnA), and SlE (Group 
B2; meeting ≥4 ACR criteria with at least 1 non-skin-
related, non-AnA-related criterion) (9). 
The examined data of the patients included: age, 
sex, age at the disease onset (defined as the initial 
manifestation clearly attributable to DlE), age at the 
examination of lBTs, ACR criteria, and type of the de-
posited immunoreactant (IR) in lBTs on both lesional 
and SPnl skin. lBT examination of skin biopsy is one 
of the routine tests for lE patients in our department. 
In this study, we retrospectively reviewed the DIF ex-
aminations of these patients according to the pres-
ence, type, and composition of IRs on sun-exposed 
lesional skin (the face or upper limbs) and on SPnl 
skin (the buttocks). The DIF examinations had been 
performed with standard techniques using fluores-
cein-labeled antisera to human immunoglobulin G 
(IgG), immunoglobulin A (IgA), immunoglobulin M 
(IgM), and C3 as previously described (6). The skin bi-
opsies were assessed by one blinded pathologist, and 
DIF patterns were interpreted according to the stan-
dard criteria (7,15,16). Positive lBT was defined as a 
presence of one or more IR (IgM, IgG, IgA, and /or C3) 
at the dermoepidermal junction, with linear staining 
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in a continuous band and/or a continuous and dis-
crete granular pattern (15).
Statistical analysis were performed comparing 
the two main groups (DlE: Group A; SlE: Group B) 
and then three subgroups (DlE: Group A; borderline 
SlE: Group B1; SlE: Group B2). Statistical analysis was 
carried out using the Statistical Package for Social Sci-
ences (SPSS, Chicago, Il, USA), version 15. Quantita-
tive data were presented as mean ± Standard Deri-
vation (SD), while qualitative data were presented 
as number (n) and percentage (%). non-parametric 
tests were performed because of the non-homoge-
neous distribution of data, and a P value of <0.05 was 
considered statistically significant. The chi-squared 
test was used to compare the qualitative data be-
tween the two groups. The Fisher exact test was used 
instead of the chi-squared test when the expected 
count in any cell was <5. The comparison between 
quantitative data for the two groups was done using 
the Mann-Whitney U test.
RESULTS 
Patient groups
A total of 94 patients were studied; 41 (43.6%) of 
them were included in Group A, and the remaining 53 
(56.4%) were included in Group B. In Group B, 23 (24.5%) 
patients were included in the Group B1 and the remain-
ing 30 (31.9%) were included in Group B2. no signifi-
cant difference was observed between the groups in 
terms of sex distribution, age at disease onset, disease 
duration, and age at lBT examination (Table 1). The ACR 
criteria for all groups are shown in Table 2. 
Cutaneous immunopathological findings
A. LBT results for lesional skin: 
IR deposition was observed in all patients. Total 
IgM, total C3, and IgG+IgM+IgA+C3 depositions were 
higher, but single IgG deposition was lower in Group 
B than Group A. In the subgroups, total IgM deposi-
tion was the highest in Group B2, and total C3, >1 
IRs, IgG+IgM+C3, and IgG+IgM+IgA+C3 depositions 
were higher in Group B2 than Group A. Isolated single 
IR deposition was lower in Group B2 than in Group A, 
and single IgG deposition was the lowest in Group B2 
(Table 3). 
B.  LBT results for SPNL skin: 
At least one IR deposition was observed in 42 
(44.7%) patients. lBT positivity, total IgM, total IgG, 
total C3, single IgM, >1 IRs, and double conjugate IR 
depositions were higher in Group B than Group A. In 
the subgroups, lBT positivity, total IgM, and IgG de-
positions were lowest in Group A. Total C3, >1 IRs, and 
double conjugate IR depositions (especially IgM+C3) 
were the highest in Group B2. Isolated single IR de-
position was the highest in Group B1, especially the 
deposition of single IgM, which was higher in Group 
B1 than Group A. IgG+IgM+C3 deposition was higher 
in Group B2 than Group A (Table 4).
DISCUSSION
In this study we investigated the immunopatho-
logical findings on lesional and SPnl skin of patients 
with lE that had discoid lesions and thus aimed to de-
termine the place of borderline SlE among these pa-
tients on the lE spectrum. There are a limited number 
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0.813 0.272 0.073 0.134
Abbreviations: SD: Standard Deviation; DlE: discoid lupus erythematosus; SlE: systemic lupus erythematosus;  
lBT: lupus band test; nA: not applicable 
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of reports in the literature comparing the cutaneous 
IR depositions in patients with lE with discoid lesions 
according to the presence of concomitant systemic 
involvement. Furthermore, they had number of pa-
tients and the results varied between studies (19,20). 
To our knowledge, this was the first comprehensive 
study examining lBT results both on lesional and 
SPnl skin related to the presence of systemic involve-
ment in patients with lE that had discoid lesions.
The lBT results on lesional skin of our patients with 
lE and discoid lesions showed a predominant depo-
sition of IgG in accordance with most other authors, 
Table 2. American College of Rheumatology (ACR) criteria of the patient groups 













































































Abbreviations: AnA: antinuclear antibodies; DlE: discoid lupus erythematosus; SlE: systemic lupus erythematosus.
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Table 3. lupus band test (lBT) results on lesional skin
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22 (23.4) 5 (12.2) 17 (32.1) 6 (26.1) 11 (36.7) 0.024 0.182 0.413 0.015
Abbreviations: IgA: Immunoglobulin A; IgM: Immunoglobulin M; IR: immunoreactant; DlE: discoid lupus erythematosus; 
SlE: systemic lupus erythematosus; nA: not applicable 
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but the dominance of IgM has also been emphasized 
by some others (22-24). Kontos et al. specified that IgG 
is more specific for lE lesions, while IgM is more sensi-
tive (25). Additionally, the most frequently observed 
IR was IgM on the lesional lBT in patients diagnosed 
with SlE, and it was demonstrated by various authors 
that the most frequently detected patterns were the 
IgM+IgG (11) or IgM+C3 combinations (25-27), as was 
the case in our study. However, none of these studies 
reported the morphological properties of the lesional 
skin or the presence of concomitant discoid lesions 
in patients with SlE (27). Thus, it is not appropriate to 
compare these findings with the results in our patients 
with lE with discoid lesions. nevertheless, because 
the IgM deposition on lesional lBT was the highest in 
Group B2, it can be estimated that Group B1 may be 
closer to DlE in terms of systemic involvement. 
When we reviewed the studies comparing lesional 
lBT results according to the presence of concomitant 
systemic involvement in patients with DlE, we found 
only one report by David-Bajar et al. This study that 
included 11 patients with DlE found that the lesional 
lBT results (particularly C3, IgG and/or IgM) did not 
show any significant difference between the patients 
with and without systemic involvement (66.6% and 
80%, respectively), in contrast to our study. However, 
the IR types and combinations were not shown in de-
tail (20). The specificity and predictive value of the lBT 
increase together with the IR quantity in the dermo-
epidermal junction has also been demonstrated by 
various authors (10,26). In our study, due to the less 
single IgG deposition in Group B and a significantly 
lower ratio of this deposition pattern in the Group 
B2, Group B1 is closer to DlE. However, it is placed 
between DlE and SlE on the spectrum in terms of 
the deposition of >1 IRs, IgG+IgM+C3, and quadruple 
conjugate on lesional lBT.
The importance of complement deposition at the 
dermoepidermal junction in patients with lE is con-
tradictive, and its value in the diagnosis of DlE is un-
known (24). Isolated C3 deposition is usually rare, as 
in our study, and it mostly presents together with IgM 
and/or IgG (28). Although it has been claimed that C3 
is the most frequent deposition subsequent to IgM 
on lesional lBT in patients with SlE, contrary to the 
results in our study, no data showing the significance 
of C3 deposition in terms of systemic involvement 
was found (11,25-27). Our patients in the Group B1 
were placed between DlE and SlE in terms of lesional 
C3 deposition. 
When we reviewed the lBT results on SPnl skin 
of patients with lE with discoid lesions, the results 
were generally negative in patients with ClE (espe-
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Table 4. lupus band test (lBT) results on sun-protected non-lesional skin
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IgG+IgM+C3 5 (5.3) 0 (0.0) 5 (9.4) 1 (4.3) 4 (13.3) 0.066 0.359 0.374 0.028
Quadruplet 
conjugate
1 (1.1) 0 (0.0) 1 (1.9) 0 (0.0) 1 (3.3) 1.000 nA 1.000 0.423
Abbreviations: IgG: Immunoglobulin G; IgM: Immunoglobulin M; IR: immunoreactant; DlE: discoid lupus erythematosus; 
SlE: systemic lupus erythematosus; nA: not applicable 
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cially with isolated cutaneous findings), but deposi-
tions of some IRs (especially IgM and/or C3, less often 
IgG) were also rarely found in patients with DlE. The 
most frequently deposited IR was usually IgM, as in 
our study; however, Cardinali et al. found that C3 de-
position was more dominant. nevertheless, the per-
centage of IgG deposition on SPnl skin was some-
what higher in our study when compared to previous 
studies (16-19).
Despite the diagnostic value of positive lBT on 
SPnl skin in patients with DlE, studies showing the 
deposited IR type and quantity that can be related to 
systemic involvement are insufficient (19,20). David-
Bajar et al. did not determine any IR on SPnl skin in pa-
tients with DlE without systemic involvement, while 
IgG and/or IgM and C3 depositions were observed in 
66.6% of these patients with systemic involvement 
(20). In contrast, we found IR deposition on SPnl skin 
in Group A with a low incidence (17.1%) and in Group 
B (66%) with a high incidence. In another study, a total 
of 65 patients from different ClE groups were exam-
ined by Cardinali et al. These authors showed that the 
most frequently deposited component on the lBT of 
SPnl skin in 40 patients with DlE (33 without systemic 
involvement, 7 with systemic involvement) was C3 (in 
57.6% of the patients without systemic involvement 
and in 85.7% of the patients with systemic involve-
ment), while the most frequently observed immuno-
globulin was IgM (in 24.2% of the patients without 
systemic involvement and 57.1% of the patients with 
systemic involvement). The second most frequently 
observed immunoglobulin was IgG, and the deposi-
tion was only observed in 6% of the patients with DlE 
without systemic involvement. Although it was found 
that the incidence of all IRs observed on SPnl skin 
in patients with ClE with systemic involvement was 
high, no significant difference was observed when 
compared with patients with ClE without systemic in-
volvement. However, this comparison was not made 
between chronic ClE patients who only had discoid 
lesions like in our study (19).
In our patients with lE with discoid lesions, the 
IR types deposited on SPnl skin were determined to 
be IgM, C3, and IgG, in order of their frequencies. It 
was observed that the lBT positivity and the deposi-
tions of IgM, IgG, and C3 on SPnl skin were higher in 
Group B than Group A. In the literature, lBT positiv-
ity on SPnl skin has generally been observed in 25-
70% of patients with SlE, and there are some reports 
demonstrating the dominant deposition of IgM or C3 
(11,14). However, the presence of cutaneous involve-
ment as well as the discoid lesions at the time of the 
biopsy in these patients is uncertain. In our study, 
Group B1 was similar to SlE in terms of lBT positivity 
and the depositions of IgM and IgG on SPnl skin, but 
closer to DlE in terms of total C3 deposition. More-
over, some authors have noted that the lBT positivity 
on SPnl skin is of prognostic importance, especially 
with increasing quantities of IRs, and having ≥3 IR de-
positions on SPnl skin has the highest specificity for 
SlE diagnosis when compared with other tests (10-
15). In our study, a higher percentage of >1 IRs de-
position and double conjugate deposition in Group 
B2 compared with Group B1 indicate that group B1 
is similar to DlE in terms of the number of deposited 
IRs on SPnl skin.
As a result, considering the place of patients with 
borderline SlE with discoid lesions on the lE spec-
trum, lBT examinations have resulted in both similar 
and distinct findings compared with DlE and SlE. 
However, due to certain limitations of our study such 
as its single-centered, cross-sectional, and retrospec-
tive nature, excluding patients with other lE-specific 
skin lesions, lack of follow-up lBT findings in patients 
with borderline SlE, and lack of the correlation of 
these lBT results with clinical and laboratory features, 
more extensive prospective follow-up studies are re-
quired in order to obtain more significant data. 
CONCLUSION
In conclusion, deposition of multiple IRs in the 
forms of conjugates on the lBT of SPnl skin in pa-
tients with lE with discoid lesions may be an indica-
tion of possible systemic involvement. Despite the 
higher lBT positivity on SPnl skin in patients with 
borderline SlE with discoid lesions compared with 
DlE, the presence of lower deposition of multiple IRs 
than in SlE indicates that the placement of border-
line SlE with discoid lesions in the lE spectrum is still 
questionable.  
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